Segal E, Sandovsky-Losica H, Nussbaum S
Mycopathologia. 1985 Feb;89(2):113-8. doi: 10.1007/BF00431479.
This study describes humoral and cell mediated immune (CMI) responses detected in cyclophosphamide (CY) treated animals who were vaccinated with Candida albicans ribosomes and were protected against systemic candidiasis (previous study). Mice treated with CY and vaccinated with C. albicans ribosomes revealed CMI responses towards the ribosomes as measured in vivo by the foot pad swelling test and in vitro by the lymphocyte transformation assay. Both reactions were higher in CY treated and ribosome vaccinated mice than in controls (mice that were only vaccinated). Humoral immune responses were measured by the enzyme linked immunosorbent assay (ELISA). Anti ribosomal antibody titer contrary to the CMI responses was lower in CY treated animals than in non treated controls. These data point to a possible explanation of the mechanisms underlying the ribosomal vaccinations in CY treated hosts, and show the potential of such vaccinations in compromised individuals.
本研究描述了在接受环磷酰胺（CY）治疗、接种白色念珠菌核糖体并受到系统性念珠菌病保护的动物（先前研究）中检测到的体液免疫和细胞介导免疫（CMI）反应。用CY治疗并接种白色念珠菌核糖体的小鼠表现出对核糖体的CMI反应，通过足垫肿胀试验在体内和淋巴细胞转化试验在体外进行测量。在接受CY治疗并接种核糖体的小鼠中，这两种反应均高于对照组（仅接种疫苗的小鼠）。通过酶联免疫吸附测定（ELISA）测量体液免疫反应。与CMI反应相反，接受CY治疗的动物中抗核糖体抗体滴度低于未治疗的对照组。这些数据指出了CY治疗宿主中核糖体疫苗接种潜在机制的一种可能解释，并显示了这种疫苗接种在免疫功能受损个体中的潜力。
